Literature DB >> 16573605

Adiponectin levels and arteriosclerotic risk factors in pediatric renal transplant recipients.

Sevcan A Bakkaloglu1, Oguz Soylemezoglu, Necla Buyan, Suna Ozhan Oktar, Tohru Funahashi, Hatice Pasaoglu, Atilla H Elhan, Harun Peru, Enver Hasanoglu.   

Abstract

ADPN, a recently discovered adipocytokine, has attracted great attention because of its anti-atherogenic properties. It was suggested as a protective factor for the cardiovascular system because of its close correlation with several risk factors. Our aim was to investigate serum ADPN levels in pediatric RTR and to document possible relationships between ADPN and arteriosclerotic risk factors. Twenty-one RTR, aged 16.3 +/- 4.0 yr, and 23 healthy age and sex-matched control subjects were enrolled in this study. Serum lipid/lipoprotein fractions, homocysteine and ADPN levels as well as intima-media thickness of the cIMT were determined in both groups. Significantly higher serum ADPN (p < 0.001) and homocysteine (p < 0.05) levels as well as higher cIMT (p < 0.001) were found in RTR compared with the control subjects, whereas apolipoprotein B and lipoprotein (a) levels were not significantly different. HDL cholesterol was positively correlated with log ADPN (r = 0.585, p < 0.01). There were inverse correlations between log time post-transplantation and log ADPN as well as HDL cholesterol (r = -0.438, p < 0.05 and r = -0.578, p < 0.05, respectively). There were no correlation between log ADPN, log homocysteine, log apolipoprotein B, lipoprotein (a), creatinine clearance and cumulative steroid dose. Despite reasonable lipid profiles and remarkably elevated ADPN levels, our pediatric RTR with stable graft function displayed a risk for arteriosclerosis because of increased cIMT and mild hyperhomocysteinemia. Regarding the close positive correlation between ADPN and HDL cholesterol, it could be speculated that ADPN is a novel negative surrogate marker of arteriosclerosis. To our knowledge, this is the only report investigating levels and diverse correlates of ADPN in a pediatric RTR group. Further studies in larger groups of recipients are needed to clarify the interaction between arteriosclerotic risk factors and ADPN.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16573605     DOI: 10.1111/j.1399-3046.2005.00422.x

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  6 in total

Review 1.  Increased intima-media thickness of the carotid artery in childhood: a systematic review of observational studies.

Authors:  Christophe Lamotte; Catalina Iliescu; Christian Libersa; Frédéric Gottrand
Journal:  Eur J Pediatr       Date:  2010-10-27       Impact factor: 3.183

2.  High serum adiponectin concentration in children with chronic kidney disease.

Authors:  Kristina F Möller; Christina Dieterman; Lena Herich; Ilka A Klaassen; Markus J Kemper; Dirk E Müller-Wiefel
Journal:  Pediatr Nephrol       Date:  2011-08-09       Impact factor: 3.714

3.  Adiponectin in children and young adults with focal segmental glomerulosclerosis.

Authors:  Christine B Sethna; Valerie Boone; Jonas Kwok; Daniel Jun; Howard Trachtman
Journal:  Pediatr Nephrol       Date:  2015-06-27       Impact factor: 3.714

Review 4.  Adiponectin, cardiovascular disease, chronic kidney disease: emerging data on complex interactions.

Authors:  Megan M Lo; Mark Mitsnefes
Journal:  Pediatr Nephrol       Date:  2011-02-21       Impact factor: 3.714

5.  Serum adiponectin levels and mortality after kidney transplantation.

Authors:  Ahsan Alam; Miklos Z Molnar; Maria E Czira; Anna Rudas; Akos Ujszaszi; Kamyar Kalantar-Zadeh; Laszlo Rosivall; Istvan Mucsi
Journal:  Clin J Am Soc Nephrol       Date:  2012-12-06       Impact factor: 8.237

6.  L-4F treatment reduces adiposity, increases adiponectin levels, and improves insulin sensitivity in obese mice.

Authors:  Stephen J Peterson; George Drummond; Dong Hyun Kim; Ming Li; Adam L Kruger; Susumu Ikehara; Nader G Abraham
Journal:  J Lipid Res       Date:  2008-04-19       Impact factor: 5.922

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.